Introduction {#Sec1}
============

In a previous issue of *Critical Care*, Lorente and colleagues \[[@CR1]\] reported the results of a prospective study aiming at evaluating the impact of continuous control of cuff pressure (P~cuff~) on the incidence of ventilator-associated pneumonia (VAP). They included a large number of patients intubated and ventilated for more than 48 hours (150 patients in a continuous control group and 134 patients in a routine care group). The target P~cuff~ was 25 cm H~2~O in both groups. Whereas the main clinical characteristics were similar in the study groups, VAP rate was significantly reduced by the use of continuous control of P~cuff~. Additionally, continuous control of P~cuff~ and use of subglottic secretion drainage were independently associated with reduced incidence of VAP. Kaplan-Meier analysis showed a significantly higher proportion of patients remaining free from VAP using continuous control of P~cuff~ compared with intermittent control using a manometer.Table 1**Characteristics of studies assessing the impact of continuous control of cuff pressure on ventilator-associated pneumonia incidence**Valencia *et al*. \[[@CR5]\] (2007)Nseir *et al*. \[[@CR4]\] (2011)Lorente *et al*. \[[@CR1]\] (2014)Number of included patients142122284Type of studyRandomized controlledRandomized controlledProspective cohortPrimary objectiveVAPMicroaspirationVAPDeviceElectronicPneumaticElectronicTarget P~cuff~, cm H~2~O252525Surgical patients, %28028Chronic respiratory disorders, %382715Oral careCHX 0.12% X3/dCHX 0.10% X3/dCHX 0.12% X3/dSemirecumbent positionYesYesYesVAP incidence in control group, %152622Reduction in VAP rate, %NS6251% P~cuff~ 20-30 cm H~2~O in intervention group7998100CHX, chlorhexidine; NS, not significant; P~cuff~, cuff pressure; VAP, ventilator-associated pneumonia; X3/d, 3 times a day.

Comparison with previous studies {#Sec2}
================================

The strengths of this study are the large number of included patients and adjustment for confounders using Cox proportional analysis. As acknowledged by the authors, the absence of randomization and blinding is one of the limitations of the study. In addition, the impact of continuous control of P~cuff~ on tracheal ischemic lesions was not evaluated. However, previous animal and clinical studies found no significant effect of this intervention on the incidence of intubation-related tracheal damage \[[@CR2],[@CR3]\]. Furthermore, efficiency of the electronic device used by the authors in continuously controlling P~cuff~ was not previously evaluated in critically ill patients.

The lower rate of VAP in patients who received continuous control of P~cuff~ is in line with the results of a recent randomized controlled study performed by our group \[[@CR4]\], although the primary outcome of that study was not VAP but abundant microaspiration of gastric content. Another randomized controlled study found no significant impact of continuously controlling P~cuff~ on VAP incidence \[[@CR5]\]. Several differences regarding the device used to control P~cuff~, study population, and design might explain the different reported results (Table [1](#Tab1){ref-type="table"}).

Microaspiration and underinflation of tracheal cuff {#Sec3}
===================================================

Microaspiration of contaminated oropharyngeal and gastric secretions is the main mechanism of entry of bacteria into the lower respiratory tract \[[@CR6]\]. Recently, several markers of microaspiration, including pepsin and salivary amylase, were described and validated \[[@CR7]--[@CR9]\]. Interestingly, these markers are quantitative, allowing accurate evaluation of microaspiration. It is well known that subsequent development of VAP is tightly correlated to the quantity of bacteria present in the lower respiratory tract \[[@CR10]\]. The use of these biomarkers in critically ill patients could be helpful in evaluating the efficiency of a new device aiming at reducing the incidence of VAP via the reduction of microaspiration, before conducting large multicenter studies to test the effect of such a device on VAP incidence.

Underinflation of the tracheal cuff is usually defined as P~cuff~ of less than 20 cm H~2~O and was identified by one prospective observational study as an independent risk factor for VAP in a subgroup of patients without antimicrobials \[[@CR11]\]. However, microaspiration could occur at higher P~cuff~ depending on tracheal anatomy and patient movements \[[@CR12]\]. In fact, microaspiration is a multifactorial process related to mechanical ventilation, tracheal tube, enteral nutrition, and general factors. Therefore, to prevent microaspiration and subsequent VAP, all of these factors, not just P~cuff~, should be taken into account.

Current practice and future studies {#Sec4}
===================================

In spite of routine manual control of P~cuff~ using a manometer, intubated critically ill patients spend a large amount of time with underinflation and overinflation (\>30 cm H~2~O) of the tracheal cuff. In a cohort of 101 critically ill patients intubated with a polyvinylchloride-cuffed tube, P~cuff~ was continuously recorded for 8 hours after manual adjustment of P~cuff~ at 25 cm H~2~O \[[@CR13]\]. Only 18 % of study patients spent 100 % of recording time with a normal (20 to 30 cm H~2~O) P~cuff~. Fifty-four percent of study patients developed cuff underinflation, 73 % developed cuff overinflation, and 44 % developed both. Subsequent studies reported similar results in patients intubated with polyurethane-cuffed tracheal tubes \[[@CR14],[@CR15]\]. Several devices aiming at continuously controlling P~cuff~, including the one used by Lorente and colleagues, are currently available on the market. Unfortunately, the efficiency of some of these devices was never tested in clinical studies. Therefore, before these devices can be used in critically ill patients, well designed and performed studies are required.

Conclusions {#Sec5}
===========

Future randomized multicenter studies should confirm the beneficial effect of continuous control of P~cuff~ on VAP incidence. Furthermore, the efficiency and cost-effectiveness of different available devices should be compared. Meanwhile, given the single-center design and the limitations of the available studies, no strong recommendation can be made regarding continuous control of P~cuff~ as a preventive measure of VAP.

See related research by Lorente *et al*., <http://ccforum.com/content/18/2/R77>
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